| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3323 |
| Trial ID | NCT05705570 |
| Disease | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies |
| Year | 2023 |
| Country | Brazil |
| Company sponsor | Hospital Israelita Albert Einstein |
| Other ID(s) | 30173220.5.0000.0071 |
| Cohort 1 | |||||||||||||
|
|||||||||||||